Loading
A phase 2 trial of TGRX-678 in chronic myeloid leukaemia, run by Shenzhen TargetRx Co., Ltd., now recruiting.
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients is a phase 2 interventional study registered as NCT06453902 by Shenzhen TargetRx Co., Ltd., with 40 participants planned, started 2024-07-15 and due to reach its primary completion in 2026-06-30. Interventions recorded: TGRX-678.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Chronic myeloid leukaemia, accelerated and blast phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia, accelerated and blast phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Shenzhen TargetRx and the tag pipeline.
Shares Shenzhen TargetRx and the tag pipeline.
Shares Chronic myeloid leukaemia, accelerated and blast phase, Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
Shares Chronic myeloid leukaemia (CML) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/